Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a clinical-stage biotechnology company focused on therapies for immune-mediated and metabolic diseases, with a particular emphasis on ophthalmology and rare retinal conditions. News about Aldeyra often centers on the progress of its RASP (reactive aldehyde species) modulator platform and its late-stage product candidates reproxalap and ADX-2191.
Investors following ALDX news can expect regular updates on regulatory milestones, such as the U.S. Food and Drug Administration’s review of the New Drug Application for topical ocular reproxalap in dry eye disease, extensions of Prescription Drug User Fee Act (PDUFA) target action dates, and feedback on proposed labeling. Aldeyra also reports on orphan drug and fast track designations from the FDA and the European Medicines Agency for ADX-2191 in primary vitreoretinal lymphoma, retinitis pigmentosa, and related inherited retinal dystrophies.
The company’s news flow includes clinical trial readouts and pipeline updates, such as Phase 2 data for ADX-629 in alcohol-associated hepatitis, preclinical results for ADX-248 in models of central nervous system diseases associated with inflammation, and decisions to prioritize next-generation RASP modulators ADX-248 and ADX-246. Aldeyra also issues releases about Special Protocol Assessment agreements, manufacturing inspections and outcomes, and participation in healthcare and ophthalmology conferences and research and development webcasts.
This ALDX news page aggregates these company communications so readers can track developments in Aldeyra’s RASP platform, ophthalmic programs, and broader immune-mediated disease pipeline over time. For investors and observers, the news stream provides context on clinical progress, regulatory interactions, and strategic pipeline decisions that shape the company’s future prospects.
Aldeyra Therapeutics (NASDAQ: ALDX) will have its CEO, Todd C. Brady, participate in a fireside conversation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 9:55 a.m. ET. The event will be accessible via a live webcast on the company's Investors & Media page and archived for 90 days. Aldeyra focuses on developing novel therapies for ocular and systemic diseases, with lead candidates like reproxalap and ADX-629 in clinical trials for conditions such as dry eye disease.
Aldeyra Therapeutics, a biotechnology company focused on immune-modulating therapies for ocular and systemic diseases, announced participation in two upcoming investor conferences. President and CEO Todd C. Brady will present at Citi's 16th Annual BioPharma Virtual Conference on September 9, 2021, at 8:50 a.m. ET, discussing next-generation retinal therapeutics. Additionally, he will be featured at H.C. Wainwright's 23rd Annual Global Investment Conference on September 13, 2021, beginning at 7:00 a.m. ET. Archived versions of these events will be available on the company's website for 90 days.
Aldeyra Therapeutics (Nasdaq: ALDX) reported its financial results for Q2 2021, highlighting a net loss of $14.9 million compared to $7.5 million in Q2 2020. Cash reserves stand at $249.7 million, sufficient to fund operations through 2023. The company anticipates results from its Phase 3 TRANQUILITY trials for reproxalap in dry eye disease by Q4 2021, alongside outcomes from Phase 2 trials of ADX-629 for immune-mediated diseases. Additionally, the FDA granted orphan drug designation for ADX-2191 in two retinal diseases, enhancing development incentives.
Aldeyra Therapeutics (Nasdaq: ALDX) has received orphan drug designation from the FDA for ADX-2191, indicated for treating retinitis pigmentosa (RP), a rare genetic eye disease affecting up to 110,000 individuals in the U.S. This designation signifies the unmet medical need in ophthalmology. ADX-2191 also holds orphan drug designation for primary vitreoretinal lymphoma and fast track designation for preventing proliferative vitreoretinopathy. These regulatory recognitions offer financial incentives under the FDA's orphan drug program, including potential marketing exclusivity.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that President and CEO Todd C. Brady, M.D., Ph.D., will participate in analyst-led fireside chats at two upcoming virtual conferences.
- BTIG Virtual Biotechnology ConferenceDate: August 9, 2021, Time: 9:30 a.m. ET
- H.C. Wainwright Ophthalmology Virtual ConferenceDate: August 17, 2021, Time: Available On-Demand from 7:00 a.m. ET
Access details are available on Aldeyra’s Investor & Media page, with archives for 90 days post-event.
Aldeyra Therapeutics (Nasdaq: ALDX) announced that the FDA has granted orphan drug designation for ADX-2191, a methotrexate treatment for primary vitreoretinal lymphoma (PVRL), a rare cancer affecting about 2,800 individuals in the U.S. annually. This designation supports clinical development and commercialization, providing tax incentives and potential seven-year marketing exclusivity. ADX-2191 is also in Phase 3 trials for preventing proliferative vitreoretinopathy, a major complication of retinal surgery. Orphan drug status can enhance funding and development prospects for Aldeyra's pipeline.
Aldeyra Therapeutics (Nasdaq: ALDX) has been included in both the Russell 3000 and Russell 2000 indexes, effective June 28, 2021. This addition reflects the company's growing market capitalization and investor interest, driven by advancements in their clinical pipeline, including reproxalap for dry eye disease and allergic conjunctivitis, and ADX-629 for systemic diseases. The Russell indexes are vital benchmarks for investment strategies, with about $10.6 trillion in assets tied to them.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced that its President and CEO, Todd C. Brady, M.D., Ph.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. A live webcast of the event will be available on the company's investor relations page and archived for 90 days afterward. Aldeyra focuses on developing treatments for immune-mediated diseases, with key products in clinical trials, including reproxalap for dry eye disease and allergic conjunctivitis.
Aldeyra Therapeutics (Nasdaq: ALDX) reported Q1 2021 financial results, highlighting significant progress in clinical trials for its lead product, reproxalap. The Phase 3 INVIGORATE Trial showed statistically significant improvement in allergic conjunctivitis symptoms. Aldeyra anticipates meeting with the FDA regarding a potential New Drug Application. The company completed a public offering, raising $125 million, ensuring financing through 2023. Q1 net loss was $11.3 million, up from $9.9 million year-over-year, primarily due to R&D expenses.
Aldeyra Therapeutics (Nasdaq: ALDX) is set to host a conference call on May 6, 2021, at 8:00 a.m. ET to discuss its financial results for Q1 2021, ending March 31, 2021. The live call can be accessed via dial-in numbers for domestic (866-211-4098) and international (647-689-6613) callers. The company focuses on developing innovative therapies for immune-mediated diseases, with lead compounds reproxalap and ADX-629 currently in clinical trials.